Fig. 5: Myc, Sam68 and Rad51 characterize breast cancers with poor clinical outcome.
From: Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51
A Cell viability percentage of scramble (scr) and short hairpin Sam68 (shSam68) ER+R (MCF7) BC cell line treated with vehicle and dinaciclib (10 nM) for 6 days. Data are represented as mean ± SEM (n = 4). *p value ≤ 0.05; **p value ≤ 0.01; ***p value ≤ 0.001. B Relative mRNA expression levels of RAD51 and MYC on scramble (scr) and short hairpin Sam68 (shSam68) ER+R (MCF7) BC cells treated with vehicle and dinaciclib for 6 days. Data are represented as fold mRNA level changes of treated scr and shSam68 over vehicle (n = 3). C Cell viability percentage in ER+R (MCF7) BC cells treated with vehicle, olaparib and dinaciclib, alone or in combination, at the indicated concentrations for 6 days. Data are represented as mean ± SD (n = 3). D Kaplan–Meier plots of relapse-free survival (RFS) probability of BC patients of all molecular subtypes stratified by high or low MYC, KHDRBS1, and RAD51 expression levels. E Schematic model showing the persistence of a BC stem-like population, characterized by high expression levels of MYC, SAM68, and RAD51, following standard anticancer therapies.
